Chikungunya vaccine study in La Réunion
Part of Infections clinical trials.
This study is for people who are eligible for the chikungunya vaccine in La Réunion. It looks at how well the vaccine works in real life, if it’s safe, and how your body responds to it.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are eligible for the chikungunya vaccine based on French health authority guidelines.
- You have social security coverage.
- You are not pregnant.
- You do not have a medical condition or treatment that makes the vaccine unsafe.
- You are not under legal guardianship, curatorship, or safeguard of justice.
- You have not received immunoglobulin, blood, or plasma in the last 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well the VLA1553 vaccine prevents chikungunya disease in parts of Brazil where the vaccine is being offered as part of a pilot program. If you live in one of those areas and have had symptoms that might be chikungunya, this study will use your health records and blood tests to check how effective the vaccine is.
This study tests a new vaccine to see if it's safe and helps protect against chikungunya virus (a mosquito-borne illness causing fever and joint pain). It's for healthy adults ages 18 to 60 who haven't recently traveled to areas with similar viruses or received certain other vaccines.
This study follows pregnant women who received the VLA1553 vaccine (for chikungunya) to see how it affects them and their babies. It compares them to pregnant women who received a different vaccine approved during pregnancy.
This trial tests a new treatment (PC-CHIK-V) for newborns whose mothers had chikungunya around the time of birth. The goal is to see if the treatment can prevent or reduce the infection in babies. Babies who are not treated will also be followed for comparison.
This study looks for Chikungunya virus in the semen of men who are currently sick with the virus, to understand how long it stays there.
This study looks at how well the shingles vaccine works in people with autoimmune inflammatory diseases. Researchers want to make sure the vaccine provides good protection for patients whose immune systems are affected by their condition or treatment.
Hear when a new Chikungunya Virus Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.